How do Ingrezza (valbenazine) and Austedo (deutetrabenazine) differ in market share?
I can’t answer this as written because the information you provided is only the drug names and a “market share td” fragment. To give a reliable comparison, I need the missing context for what “td” means (for example: “therapy days,” “treatment days,” “total drug,” or “TDD”) and which market you want (US vs. global, and what time period).
If you tell me:
- Country/region (e.g., US)
- Timeframe (e.g., 2023, latest quarter, trailing 12 months)
- Metric (“td” definition)
…I can summarize how Ingrezza vs. Austedo performed on that specific measure.
What does “td” usually mean in market-share questions?
In pharma sales and analytics, “td” is often used as shorthand in dashboards, but it varies by source. Common possibilities include:
- therapy days (or treatment days)
- total dispensed quantity
- total drug sales value
Different “td” definitions can lead to different conclusions (e.g., a drug with fewer users but higher dose intensity can score differently depending on whether you’re measuring volume, patients, or therapy days).
Where to find market-share data for Ingrezza vs. Austedo
If your goal is market share using an analytics source or dashboard, the most efficient path is to use the same provider you’re referencing (and its exact “td” definition). I can also pull and cite market data if you share the source link or the specific table you’re working from.
Quick clarification request
Reply with what “td” stands for and the geography/time period you mean (US/Global; year/quarter). Once I have that, I’ll compare Ingrezza (valbenazine) vs. Austedo (deutetrabenazine) market share using the right metric.
Sources: None cited yet (insufficient information).